
The LifeVest was designed as an intermediate-term treatment option for people at high risk for sudden cardiac arrest (SCA).
Right now, people at a high, short-term risk of SCA are typically monitored in a hospital intensive care (ICU) or coronary care unit (CCU).
With monitored beds costing up to $2,000 a day, this option quickly becomes very expensive and is primarily reserved for critical care patients.
Patients with a high, long-term risk of SCA are often candidates for an implantable cardioverter defibrillator (ICD), but this option is also expensive (up to $65,000) and requires surgery.
According to Morgan Stanley, only one out of six US patients who need an ICD actually get one.*
The LifeVest fills the therapeutic gap between hospitalization and an ICD.
The LifeVest has the same important characteristics of both an ICU/CCU and the ICD;
it continuously monitors the heart and is designed to provide prompt defibrillation when needed.
ZOLL Lifecor Corporation believes that the LifeVest has the potential to become the standard of care for intermediate-term patients.
And, in cases when an ICD is not feasible, it also can serve as a longer-term alternative.
*Cardiac Rhythm Management Conference, September 21, 2001.
|